-
1
-
-
0034600849
-
The ErbB signaling network: receptor heterodimerization in development and cancer
-
Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO. 2000; 19: 3159-67.
-
(2000)
EMBO.
, vol.19
, pp. 3159-3167
-
-
Olayioye, M.A.1
Neve, R.M.2
Lane, H.A.3
-
2
-
-
17844372539
-
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
-
Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23: 2445-59.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 2445-2459
-
-
Baselga, J.1
Arteaga, C.L.2
-
4
-
-
39649123058
-
Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk
-
Yoshida T, Okamoto I, Okabe T, et al. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer. 2008; 122 (7): 1530-8.
-
(2008)
Int J Cancer.
, vol.122
, Issue.7
, pp. 1530-1538
-
-
Yoshida, T.1
Okamoto, I.2
Okabe, T.3
-
5
-
-
84867372753
-
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
-
van de Water JAJM, Bagci-Onder T, Agarwal AS, et al. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc Natl Acad Sci U S A. 2012; 109 (41): 16642-7.
-
(2012)
Proc Natl Acad Sci U S A.
, vol.109
, Issue.41
, pp. 16642-16647
-
-
van de Water, J.A.J.M.1
Bagci-Onder, T.2
Agarwal, A.S.3
-
6
-
-
60449094950
-
Protein and lipid kinase inhibitors as targeted anticancer agents of the RAS/RAF/MEK and PI3K/PKB pathways
-
García-Echeverría C. Protein and lipid kinase inhibitors as targeted anticancer agents of the RAS/RAF/MEK and PI3K/PKB pathways. Purinergic Signal. 2009; 5 (1): 117-25.
-
(2009)
Purinergic Signal.
, vol.5
, Issue.1
, pp. 117-125
-
-
García-Echeverría, C.1
-
7
-
-
0037099532
-
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action
-
Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002; 62 (14): 4132-41.
-
(2002)
Cancer Res.
, vol.62
, Issue.14
, pp. 4132-4141
-
-
Yakes, F.M.1
Chinratanalab, W.2
Ritter, C.A.3
-
8
-
-
2342591455
-
The discovery of receptor tyrosine kinases: targets for cancer therapy
-
Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4: 361-70.
-
(2004)
Nat Rev Cancer.
, vol.4
, pp. 361-370
-
-
Gschwind, A.1
Fischer, O.M.2
Ullrich, A.3
-
9
-
-
0034722889
-
The EGF receptor family as targets for cancer therapy
-
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000; 19: 6550-65.
-
(2000)
Oncogene.
, vol.19
, pp. 6550-6565
-
-
Mendelsohn, J.1
Baselga, J.2
-
10
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Holt JA, el al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-12.
-
(1989)
Science.
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Holt, J.A.3
el, al.4
-
11
-
-
84878926256
-
HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
-
Dent S, Oyan B, Honig A, et al. HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials. Cancer Treat Rev. 2013; 39: 622-31.
-
(2013)
Cancer Treat Rev.
, vol.39
, pp. 622-631
-
-
Dent, S.1
Oyan, B.2
Honig, A.3
-
12
-
-
0037699294
-
Strategies to target HER2/neu overexpression for cancer therapy
-
Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Updat. 2003; 6: 129-36.
-
(2003)
Drug Resist Updat.
, vol.6
, pp. 129-136
-
-
Chen, J.S.1
Lan, K.2
Hung, M.C.3
-
13
-
-
19044380618
-
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
-
Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002; 2: 127-37.
-
(2002)
Cancer Cell.
, vol.2
, pp. 127-137
-
-
Agus, D.B.1
Akita, R.W.2
Fox, W.D.3
-
14
-
-
0032127350
-
Recombinant Humanized Anti-HER2 Antibody (HerceptinTM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts
-
Baselga J, Norton L, Albanell J, et al. Recombinant Humanized Anti-HER2 Antibody (HerceptinTM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts. Cancer Res. 1998; 58: 2825-31.
-
(1998)
Cancer Res.
, vol.58
, pp. 2825-2831
-
-
Baselga, J.1
Norton, L.2
Albanell, J.3
-
15
-
-
33846566408
-
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
-
Reid A, Vidal L, Shaw H, et al. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007; 43: 481-9.
-
(2007)
Eur J Cancer.
, vol.43
, pp. 481-489
-
-
Reid, A.1
Vidal, L.2
Shaw, H.3
-
16
-
-
58249101005
-
The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) Rationale for Combining with EGFR/HER2 Inhibitors
-
Huang F, Greer A, Hurlburt W, et al. The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) Rationale for Combining with EGFR/HER2 Inhibitors. Cancer Res. 2009; 69: 161-70.
-
(2009)
Cancer Res.
, vol.69
, pp. 161-170
-
-
Huang, F.1
Greer, A.2
Hurlburt, W.3
-
17
-
-
34250647865
-
In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas
-
Larbouret C, Robert B, Navarro-Teulon I, et al. In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas. Clin Cancer Res. 2007; 13: 3356-62.
-
(2007)
Clin Cancer Res.
, vol.13
, pp. 3356-3362
-
-
Larbouret, C.1
Robert, B.2
Navarro-Teulon, I.3
-
18
-
-
33845886440
-
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
-
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2006; 355: 2733-43.
-
(2006)
N Engl J Med.
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
-
19
-
-
33747855481
-
Comparing antibody and small-molecule therapies for cancer
-
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6: 714-27.
-
(2006)
Nat Rev Cancer.
, vol.6
, pp. 714-727
-
-
Imai, K.1
Takaoka, A.2
-
20
-
-
68949212307
-
68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging
-
Liu Z, Niu G, Wang F, et al. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2009; 36: 1483-94.
-
(2009)
Eur J Nucl Med Mol Imaging.
, vol.36
, pp. 1483-1494
-
-
Liu, Z.1
Niu, G.2
Wang, F.3
-
21
-
-
62149129236
-
Therapeutic antibodies: successes, limitations and hopes for the future
-
Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009; 157 (2): 220-33.
-
(2009)
Br J Pharmacol.
, vol.157
, Issue.2
, pp. 220-233
-
-
Chames, P.1
Van Regenmortel, M.2
Weiss, E.3
-
22
-
-
0037143806
-
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
-
Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002; 100 (6): 690-7.
-
(2002)
Int J Cancer.
, vol.100
, Issue.6
, pp. 690-697
-
-
Dreier, T.1
Lorenczewski, G.2
Brandl, C.3
-
23
-
-
28944434529
-
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
-
Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006; 43: 763-71.
-
(2006)
Mol Immunol.
, vol.43
, pp. 763-771
-
-
Offner, S.1
Hofmeister, R.2
Romaniuk, A.3
-
25
-
-
77953653252
-
Antibody fragments Hope and hype
-
Nelson AL. Antibody fragments Hope and hype. mAbs. 2010; 2 (1): 77-83.
-
(2010)
mAbs.
, vol.2
, Issue.1
, pp. 77-83
-
-
Nelson, A.L.1
-
26
-
-
0037102973
-
Anti-idiotypic protein domains selected from protein A-based affibody libraries
-
Eklund M, Axelsson L, Uhlen M, et al. Anti-idiotypic protein domains selected from protein A-based affibody libraries. Proteins. 2002; 48 (3): 454-62.
-
(2002)
Proteins.
, vol.48
, Issue.3
, pp. 454-462
-
-
Eklund, M.1
Axelsson, L.2
Uhlen, M.3
-
27
-
-
78651464824
-
Affibody-based nanoprobes for HER2-expressing cell and tumor imaging
-
Gao J, Chen K, Miao Z, et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011; 32: 2141-8.
-
(2011)
Biomaterials.
, vol.32
, pp. 2141-2148
-
-
Gao, J.1
Chen, K.2
Miao, Z.3
-
29
-
-
77954034976
-
Downregulation of EGFR by a novel multivalent nanobody-liposome platform
-
Oliveira S, Schiffelers RM, Veeken J, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release. 2010; 145: 165-75.
-
(2010)
J Control Release.
, vol.145
, pp. 165-175
-
-
Oliveira, S.1
Schiffelers, R.M.2
Veeken, J.3
-
30
-
-
35348819390
-
Properties, production, and applications of camelid single-domain antibody fragments
-
Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007; (1): 13-22.
-
(2007)
Appl Microbiol Biotechnol.
, Issue.1
, pp. 13-22
-
-
Harmsen, M.M.1
De Haard, H.J.2
-
31
-
-
80052030449
-
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth
-
Roovers RC, Vosjan MJWD, Laeremans T, et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. 2011; 129 (8): 2013-24.
-
(2011)
Int J Cancer.
, vol.129
, Issue.8
, pp. 2013-2024
-
-
Roovers, R.C.1
Vosjan, M.J.W.D.2
Laeremans, T.3
-
32
-
-
55549120512
-
Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line
-
Ekerljung L, Lindborg M, Gedda L, et al. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. Biochem Biophys Res Commun. 2008; 377 (2): 489-94.
-
(2008)
Biochem Biophys Res Commun.
, vol.377
, Issue.2
, pp. 489-494
-
-
Ekerljung, L.1
Lindborg, M.2
Gedda, L.3
-
33
-
-
70350561680
-
Engineering and characterization of a bispecific HER2× EGFR-binding affibody molecule
-
Friedman M, Lindström S, Ekerljung L, et al. Engineering and characterization of a bispecific HER2× EGFR-binding affibody molecule. Biotechnol Appl Biochem. 2009; 54 (2): 121-31.
-
(2009)
Biotechnol Appl Biochem.
, vol.54
, Issue.2
, pp. 121-131
-
-
Friedman, M.1
Lindström, S.2
Ekerljung, L.3
-
34
-
-
78651464824
-
Affibody-based nanoprobes for HER2-expressing cell and tumor imaging
-
Gao J, Chen K, Miao Z, et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011; 32: 2141-8.
-
(2011)
Biomaterials.
, vol.32
, pp. 2141-2148
-
-
Gao, J.1
Chen, K.2
Miao, Z.3
-
35
-
-
33646261864
-
Tumor imaging using a picomolar affinity HER2 binding affibody molecule
-
Orlova A, Magnusson M, Eriksson TLJ, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006; 66: 4339-48.
-
(2006)
Cancer Res.
, vol.66
, pp. 4339-4348
-
-
Orlova, A.1
Magnusson, M.2
Eriksson, T.L.J.3
-
36
-
-
10644228142
-
Efficient cancer therapy with a nanobody-based conjugate
-
Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004; 64 (8): 2853-7.
-
(2004)
Cancer Res.
, vol.64
, Issue.8
, pp. 2853-2857
-
-
Cortez-Retamozo, V.1
Backmann, N.2
Senter, P.D.3
-
37
-
-
43249091515
-
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression
-
Huang L, Gainkam LOT, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008, 10 (3): 167-75.
-
(2008)
Mol Imaging Biol
, vol.10
, Issue.3
, pp. 167-175
-
-
Huang, L.1
Gainkam, L.O.T.2
Caveliers, V.3
-
38
-
-
4644247278
-
Selection and characterization of HER2/neu-binding affibody ligands
-
Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel. 2004; 17 (5): 455-62.
-
(2004)
Protein Eng Des Sel.
, vol.17
, Issue.5
, pp. 455-462
-
-
Wikman, M.1
Steffen, A.C.2
Gunneriusson, E.3
-
39
-
-
44149088593
-
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT
-
Gainkam LOT, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49 (5): 788-95.
-
(2008)
J Nucl Med.
, vol.49
, Issue.5
, pp. 788-795
-
-
Gainkam, L.O.T.1
Huang, L.2
Caveliers, V.3
-
40
-
-
22344445345
-
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics
-
Steffen AC, Wikman M, Tolmachev V, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm. 2005; 20 (3): 239-48.
-
(2005)
Cancer Biother Radiopharm.
, vol.20
, Issue.3
, pp. 239-248
-
-
Steffen, A.C.1
Wikman, M.2
Tolmachev, V.3
-
41
-
-
84869110616
-
The HER2-Binding Affibody Molecule (ZHER2: 342) 2 Increases Radiosensitivity in SKBR-3 Cells
-
Ekerljung L, Lennartsson J, Gedda L. The HER2-Binding Affibody Molecule (ZHER2: 342) 2 Increases Radiosensitivity in SKBR-3 Cells. PloS One. 2012; 7 (11): e49579.
-
(2012)
PloS One.
, vol.7
, Issue.11
, pp. e49579
-
-
Ekerljung, L.1
Lennartsson, J.2
Gedda, L.3
-
42
-
-
84861682414
-
Fast clearing RGD-based near-infrared fluorescent probes for in vivo tumor diagnosis
-
Cao J, Wan S, Tian J, et al. Fast clearing RGD-based near-infrared fluorescent probes for in vivo tumor diagnosis. Contrast Media Mol Imaging. 2012; 7: 390-402.
-
(2012)
Contrast Media Mol Imaging.
, vol.7
, pp. 390-402
-
-
Cao, J.1
Wan, S.2
Tian, J.3
-
43
-
-
33644857036
-
Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility
-
Albrecht H, DeNardo GL, DeNardo SJ. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. J Immunol Methods. 2006; 310 (1): 100-16.
-
(2006)
J Immunol Methods.
, vol.310
, Issue.1
, pp. 100-116
-
-
Albrecht, H.1
DeNardo, G.L.2
DeNardo, S.J.3
-
44
-
-
33644694918
-
Novel and simple ELISA-based method for antibody affinity determination
-
Bobrovnik SA, Komisarenko SV, Ilyina LV. Novel and simple ELISA-based method for antibody affinity determination. Ukr Biokhim Zh. 2004, 77 (2): 169-74.
-
(2004)
Ukr Biokhim Zh
, vol.77
, Issue.2
, pp. 169-174
-
-
Bobrovnik, S.A.1
Komisarenko, S.V.2
Ilyina, L.V.3
-
45
-
-
0036201921
-
Effects of cloud-point grafting, chain length, and density of PEG layers on competitive adsorption of ocular proteins
-
Kingshott P, Thissen H, Griesser HJ. Effects of cloud-point grafting, chain length, and density of PEG layers on competitive adsorption of ocular proteins. Biomaterials. 2002; 23 (9): 2043-56.
-
(2002)
Biomaterials.
, vol.23
, Issue.9
, pp. 2043-2056
-
-
Kingshott, P.1
Thissen, H.2
Griesser, H.J.3
-
46
-
-
0344851745
-
Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases
-
Edwards III CK, Martin SW, Seely J, et al. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev. 2003; 55 (10): 1315-36.
-
(2003)
Adv Drug Deliv Rev.
, vol.55
, Issue.10
, pp. 1315-1336
-
-
Edwards I.I.I, C.K.1
Martin, S.W.2
Seely, J.3
-
47
-
-
0027077805
-
Selective labeling of a-or ?-amino groups in peptides by the Bolton-Hunter reagent
-
Gaudriault G, Vincent JP. Selective labeling of a-or ?-amino groups in peptides by the Bolton-Hunter reagent. Peptides. 1992; 13 (6): 1187-92.
-
(1992)
Peptides.
, vol.13
, Issue.6
, pp. 1187-1192
-
-
Gaudriault, G.1
Vincent, J.P.2
-
48
-
-
44149088593
-
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT
-
Gainkam LOT, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49 (5): 788-95.
-
(2008)
J Nucl Med.
, vol.49
, Issue.5
, pp. 788-795
-
-
Gainkam, L.O.T.1
Huang, L.2
Caveliers, V.3
-
49
-
-
0142123347
-
Determination of antibody affinity by ELISA
-
Bobrovnik SA. Determination of antibody affinity by ELISA. Theory. J Biochem Biophys Methods. 2003; 57 (3): 213-36.
-
(2003)
Theory. J Biochem Biophys Methods.
, vol.57
, Issue.3
, pp. 213-236
-
-
Bobrovnik, S.A.1
-
50
-
-
0023258208
-
Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay
-
Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods. 1987; (1): 173-9.
-
(1987)
J Immunol Methods.
, Issue.1
, pp. 173-179
-
-
Beatty, J.D.1
Beatty, B.G.2
Vlahos, W.G.3
-
51
-
-
0034773992
-
The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities
-
Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37: 3-8.
-
(2001)
Eur J Cancer.
, vol.37
, pp. 3-8
-
-
Yarden, Y.1
-
52
-
-
32044464123
-
Epidermal growth factor receptor (EGFR) signaling in cancer
-
Normanno N, Luca AD, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366: 2-16.
-
(2006)
Gene.
, vol.366
, pp. 2-16
-
-
Normanno, N.1
Luca, A.D.2
Bianco, C.3
-
53
-
-
84883489054
-
HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling
-
Hartman Z, Zhao H, Agazie YM. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 2013; 32: 4169-80.
-
(2013)
Oncogene.
, vol.32
, pp. 4169-4180
-
-
Hartman, Z.1
Zhao, H.2
Agazie, Y.M.3
-
54
-
-
32944459561
-
Activation of the Nuclear Factor ?B Pathway by Astrocyte Elevated Gene-1: Implications for Tumor Progression and Metastasis
-
Emdad L, Sarkar D, Su Z, et al. Activation of the Nuclear Factor ?B Pathway by Astrocyte Elevated Gene-1: Implications for Tumor Progression and Metastasis. Cancer Res. 2006; 66: 1509-16.
-
(2006)
Cancer Res.
, vol.66
, pp. 1509-1516
-
-
Emdad, L.1
Sarkar, D.2
Su, Z.3
-
55
-
-
70349459893
-
The Multifaceted Role of MTDH/AEG-1 in Cancer Progression
-
Hu G, Wei Y, Kang Y. The Multifaceted Role of MTDH/AEG-1 in Cancer Progression. Clin Cancer Res. 2009; 15: 5615-20.
-
(2009)
Clin Cancer Res.
, vol.15
, pp. 5615-5620
-
-
Hu, G.1
Wei, Y.2
Kang, Y.3
-
56
-
-
33751257780
-
Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc
-
Lee S, Su Z, Emdad L, et al. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Prog Nucleic Acid Res Mol Biol. 2006; 103: 17390-5.
-
(2006)
Prog Nucleic Acid Res Mol Biol.
, vol.103
, pp. 17390-17395
-
-
Lee, S.1
Su, Z.2
Emdad, L.3
-
57
-
-
0025780991
-
Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc
-
Denis N, Kitzis A, Kruh J, et al. Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc. Oncogene. 1991; 6: 1453-7.
-
(1991)
Oncogene.
, vol.6
, pp. 1453-1457
-
-
Denis, N.1
Kitzis, A.2
Kruh, J.3
-
58
-
-
0035958062
-
Akt/PKB Activity Is Required for Ha-Ras-mediated Transformation of Intestinal Epithelial Cells
-
Sheng H, Shao J, Dubios RN. Akt/PKB Activity Is Required for Ha-Ras-mediated Transformation of Intestinal Epithelial Cells. J Biol Chem. 2001; 276: 11498-504.
-
(2001)
J Biol Chem.
, vol.276
, pp. 11498-11504
-
-
Sheng, H.1
Shao, J.2
Dubios, R.N.3
-
59
-
-
0023726412
-
Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity
-
Rajagopalan S, Politi PM, Sinha BK, et al. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988; 48 (17): 4766-9.
-
(1988)
Cancer Res.
, vol.48
, Issue.17
, pp. 4766-4769
-
-
Rajagopalan, S.1
Politi, P.M.2
Sinha, B.K.3
-
60
-
-
67649872364
-
Engineered protein scaffolds as next-generation antibody therapeutics
-
Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. 2009; 13: 245-55.
-
(2009)
Curr Opin Chem Biol.
, vol.13
, pp. 245-255
-
-
Gebauer, M.1
Skerra, A.2
-
61
-
-
0037108686
-
Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer
-
Kono K, Takahashi A, Ichihara F, et al. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. 2002; 62 (20): 5813-7.
-
(2002)
Cancer Res.
, vol.62
, Issue.20
, pp. 5813-5817
-
-
Kono, K.1
Takahashi, A.2
Ichihara, F.3
-
62
-
-
34948822890
-
EGFR, HER2 and VEGF Pathways
-
Press MF, Lenz HJ. EGFR, HER2 and VEGF Pathways. Drugs. 2007; 67: 2045-75.
-
(2007)
Drugs.
, vol.67
, pp. 2045-2075
-
-
Press, M.F.1
Lenz, H.J.2
-
63
-
-
1642422374
-
Association with membrane protrusions makes erbB2 an internalization-resistant receptor
-
Hommelgaard AM, Lerdrup M, Deurs B. Association with membrane protrusions makes erbB2 an internalization-resistant receptor. Mol Biol Cell. 2004; 15: 1557-67.
-
(2004)
Mol Biol Cell.
, vol.15
, pp. 1557-1567
-
-
Hommelgaard, A.M.1
Lerdrup, M.2
Deurs, B.3
-
64
-
-
0029021518
-
Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research
-
Earp HS, Dawson TL, Li X, et al. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995; 35: 115-32.
-
(1995)
Breast Cancer Res Treat.
, vol.35
, pp. 115-132
-
-
Earp, H.S.1
Dawson, T.L.2
Li, X.3
-
65
-
-
0024456425
-
Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions
-
Tauchi K, Hori S, Itoh H, et al. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. Virchows Arch. 1989; 416: 65-73.
-
(1989)
Virchows Arch.
, vol.416
, pp. 65-73
-
-
Tauchi, K.1
Hori, S.2
Itoh, H.3
-
66
-
-
0028610516
-
Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma
-
Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol. 1994; 47: 914-9.
-
(1994)
J Clin Pathol.
, vol.47
, pp. 914-919
-
-
Dam, P.A.1
Vergote, I.B.2
Lowe, D.G.3
-
67
-
-
84858984798
-
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
-
Luca AD, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012; 16: S17-S27.
-
(2012)
Expert Opin Ther Targets.
, vol.16
, pp. S17-S27
-
-
Luca, A.D.1
Maiello, M.R.2
D'Alessio, A.3
-
68
-
-
65549113479
-
Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis
-
Yu C, Chen K, Zheng H, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis. 2009; 30: 894-901.
-
(2009)
Carcinogenesis.
, vol.30
, pp. 894-901
-
-
Yu, C.1
Chen, K.2
Zheng, H.3
-
69
-
-
0037139394
-
Efficient tumor targeting by single-domain antibody fragments of camels
-
Cortez-Retamozo V, Lauwereys M, Gobert M, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 2002; 98 (3): 456-62.
-
(2002)
Int J Cancer.
, vol.98
, Issue.3
, pp. 456-462
-
-
Cortez-Retamozo, V.1
Lauwereys, M.2
Gobert, M.3
-
70
-
-
0030224856
-
Multiple affinity domains for the detection, purification and immobilization of recombinant proteins
-
Nilsson J, Larsson M, Stahl S, et al. Multiple affinity domains for the detection, purification and immobilization of recombinant proteins. J Mol Recognit. 1996; (5-6): 585-94.
-
(1996)
J Mol Recognit.
, Issue.5-6
, pp. 585-594
-
-
Nilsson, J.1
Larsson, M.2
Stahl, S.3
-
71
-
-
0031259833
-
Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins
-
Nilsson J, Ståhl S, Lundeberg J, et al. Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Protein Expr Purif. 1997, 11 (1): 1-16.
-
(1997)
Protein Expr Purif
, vol.11
, Issue.1
, pp. 1-16
-
-
Nilsson, J.1
Ståhl, S.2
Lundeberg, J.3
-
72
-
-
0033580768
-
Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation
-
He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci. 1999; 65 (4): 355-68.
-
(1999)
Life Sci.
, vol.65
, Issue.4
, pp. 355-368
-
-
He, X.H.1
Shaw, P.C.2
Tam, S.C.3
-
73
-
-
79958167185
-
Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models
-
Ledón N, Casacó A, Casanova E, et al. Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models. Placenta. 2011; 32 (7): 531-4.
-
(2011)
Placenta.
, vol.32
, Issue.7
, pp. 531-534
-
-
Ledón, N.1
Casacó, A.2
Casanova, E.3
-
74
-
-
84915751470
-
Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
-
Dokter W, Ubink R, van der Lee M, et al. Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform. Mol Cancer Ther; 2014, 13 (11): 2618-29.
-
(2014)
Mol Cancer Ther
, vol.13
, Issue.11
, pp. 2618-2629
-
-
Dokter, W.1
Ubink, R.2
van der Lee, M.3
|